Wells Fargo
ADPT icon

Wells Fargo’s Adaptive Biotechnologies ADPT Stock Holding History

Wells Fargo’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.28M Buy
152,727
+70,932
+87% +$1.09M ﹤0.01% 3205
2026
Q1 		$1.14M Sell
81,795
-108,589
-57% -$1.73M ﹤0.01% 3667
2025
Q4 		$3.09M Buy
190,384
+75,599
+66% +$1.23M ﹤0.01% 3088
2025
Q3 		$1.72M Buy
114,785
+36,013
+46% +$439K ﹤0.01% 3421
2025
Q2 		$918K Buy
78,772
+7,797
+11% +$70.8K ﹤0.01% 3745
2025
Q1 		$527K Buy
70,975
+1,689
+2% +$13K ﹤0.01% 4055
2024
Q4 		$415K Buy
69,286
+14,807
+27% +$81.6K ﹤0.01% 4318
2024
Q3 		$279K Buy
54,479
+667
+1% +$2.91K ﹤0.01% 4362
2024
Q2 		$195K Buy
53,812
+15,289
+40% +$48.5K ﹤0.01% 4527
2024
Q1 		$124K Buy
38,523
+4,145
+12% +$16K ﹤0.01% 4775
2023
Q4 		$168K Buy
34,378
+6,933
+25% +$31.6K ﹤0.01% 4572
2023
Q3 		$150K Sell
27,445
-22,372
-45% -$148K ﹤0.01% 4536
2023
Q2 		$334K Buy
49,817
+16,547
+50% +$123K ﹤0.01% 4243
2023
Q1 		$294K Buy
33,270
+9,214
+38% +$81.2K ﹤0.01% 4197
2022
Q4 		$184K Sell
24,056
-816
-3% -$6.35K ﹤0.01% 4218
2022
Q3 		$178K Sell
24,872
-10,052
-29% -$94.7K ﹤0.01% 4309
2022
Q2 		$283K Sell
34,924
-679
-2% -$5.97K ﹤0.01% 4099
2022
Q1 		$493K Buy
35,603
+12,088
+51% +$190K ﹤0.01% 4412
2021
Q4 		$660K Sell
23,515
-3,376
-13% -$103K ﹤0.01% 4448
2021
Q3 		$915K Sell
26,891
-8,450
-24% -$306K ﹤0.01% 4302
2021
Q2 		$1.44M Sell
35,341
-781,117
-96% -$30.4M ﹤0.01% 3964
2021
Q1 		$32.9M Sell
816,458
-521,369
-39% -$28.2M 0.01% 1297
2020
Q4 		$79.1M Buy
1,337,827
+234,854
+21% +$12.1M 0.02% 745
2020
Q3 		$53.6M Buy
1,102,973
+191,746
+21% +$8.06M 0.01% 831
2020
Q2 		$44.1M Buy
911,227
+26,293
+3% +$959K 0.01% 910
2020
Q1 		$24.6M Buy
884,934
+666,308
+305% +$18.6M 0.01% 1133
2019
Q4 		$6.54M Buy
218,626
+3,858
+2% +$111K ﹤0.01% 2328
2019
Q3 		$6.64M Buy
214,768
+109,969
+105% +$4.49M ﹤0.01% 2295
2019
Q2 		$5.06M Buy
+104,799
New +$4.64M ﹤0.01% 2564

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Wells Fargo's ADPT Position: Q2 2026 in Review

Wells Fargo increased its Adaptive Biotechnologies (ADPT) stake by 87% in Q2 2026, buying an estimated $1.09M and bringing the position to 152,727 shares worth $3.28M. The position accounts for ﹤0.01% of the portfolio, ranked #3205.

Wells Fargo first reported a position in ADPT in Q2 2019 and has held it in 29 quarters since. The position peaked at $79.1M in Q4 2020. 301 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Wells Fargo held 152,727 shares of Adaptive Biotechnologies worth $3.28M as of Q2 2026.
  • Wells Fargo bought 70,932 Adaptive Biotechnologies shares in Q2 2026, an estimated $1.09M.
  • Adaptive Biotechnologies made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3205 holding.
  • Wells Fargo first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 29 quarters since.
  • Wells Fargo's Adaptive Biotechnologies position peaked at $79.1M in Q4 2020.
  • 301 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.